

 Early Warning System

EIB-20230422

WANDERCRAFT (IEU LS)



## Quick Facts

<b>Countries</b>	France
<b>Financial Institutions</b>	European Investment Bank (EIB)
<b>Status</b>	Approved
<b>Bank Risk Rating</b>	U
<b>Voting Date</b>	2023-12-28
<b>Borrower</b>	WANDERCRAFT SAS
<b>Sectors</b>	Industry and Trade
<b>Investment Type(s)</b>	Loan
<b>Investment Amount (USD)</b>	\$ 27.67 million
<b>Project Cost (USD)</b>	\$ 55.34 million



---

## Project Description

According to the Bank's website, the project concerns the promoter's development of a hands-free walk exoskeleton used for medical rehabilitation and to improve wheelchair patients' mobility.

The promoter is already commercialising Atalante, an exoskeleton for stroke patient rehabilitation. Atalante enables these patients to re-learn how to walk by recovering their gait, more effectively than both manual rehabilitation techniques and 1st generation exoskeletons. In addition, Wandercraft is developing Eve, a personal exoskeleton for wheelchair users. By improving their daily life mobility, the Company's objective is to decrease wheelchair-related pathologies and negative impacts, such as unemployment or depression.



---

### Early Warning System Project Analysis

The project concerns investments in research and development for which no significant residual impact on the environment is expected.



---

## Investment Description

- European Investment Bank (EIB)



---

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	WANDERCRAFT SAS	Client	-

---



---

## Contact Information

*No contacts available at the time of disclosure.*

### ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

### ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: [complaints@eib.org](mailto:complaints@eib.org), by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: [http://www.eib.org/attachments/strategies/complaints\\_mechanism\\_policy\\_en.pdf](http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf)

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



---

## Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - WANDERCRAFT \(IEU LS\)](#)
- [WANDERCRAFT \(IEU LS\)](#)

## Media

- [France: Medical robotics company Wandercraft receives €25 million in EIB financing to advance self-](#)





---

### Other Related Projects

- EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL